www.imdelltra.com Open in urlscan Pro
54.69.71.127  Public Scan

Form analysis
0 forms found in the DOM

Text Content

WELCOME!

We would like to use cookies and other similar technologies to personalize
content and ads, as well as to provide social media features on this website.
This may include collecting your sensitive data, such as information identifying
you as seeking treatment for a health condition. We may also share this
information with third party providers, a list of which may be viewed by
clicking on “Settings”.

By clicking “Accept” you are consenting to both the collection and sharing of
your sensitive data by Amgen. If you do not wish to consent, choose “Decline”.
To manage your preferences or withdraw your consent, please visit “Your Cookie
Preferences” on the bottom of the website at any time. 

Nevada/Washington Residents: you must select Decline.

By using any of our websites, you are agreeing to our Terms of Use.

Do not sell or share my personal information
Decline Accept Settings
Ok
Decline
Strictly Necessary Cookies
Functional Cookies
Performance
Social Media Cookies
Settings
Cookie declaration [#IABV2SETTINGS#] About
 Strictly Necessary Cookies (5)  Functional Cookies (1)  Performance (1)  Social
Media Cookies (9)  Unknown (1)

NameProviderPurposeExpiryTypeINGRESSCOOKIEPulsepointThis cookie is used to
distinguish between humans and bots. SessionHTTP1.gifCookiebotUsed to count the
number of sessions to the website, necessary for optimizing CMP product
delivery. SessionPixelASP.NET_SessionIdwww.imdelltra.comPreserves the visitor's
session state across page requests.SessionHTTPCookieConsentCookiebotStores the
user's cookie consent state for the current domain1
yearHTTPsxa_sitewww.imdelltra.comImproves website speed and implements content
through a Content Delivery Network (CDN). SessionHTTP

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages.    If you do not allow these cookies then
some or all of these services may not function properly.

NameProviderPurposeExpiryTypeshell#langwww.imdelltra.comThis cookie is used to
determine the preferred language of the visitor and sets the language
accordingly on the website, if possible.SessionHTTP

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site.    All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

NameProviderPurposeExpiryTypeSC_ANALYTICS_GLOBAL_COOKIEwww.imdelltra.comUsed by
Sitecore Engagement Analytics to identify the visitor on repeat visits to the
website.399 daysHTTP

These cookies are set by a range of social media services that we have added to
the site to enable you to share our content with your friends and networks. They
are capable of tracking your browser across other sites and building up a
profile of your interests. This may impact the content and messages you see on
other websites you visit.    If you do not allow these cookies you may not be
able to use or see these sharing tools.

NameProviderPurposeExpiryType_uetsidMicrosoftUsed to track visitors on multiple
websites, in order to present relevant advertisement based on the visitor's
preferences. PersistentHTML_uetsid_expMicrosoftContains the expiry-date for the
cookie with corresponding name. PersistentHTML_uetvidMicrosoftUsed to track
visitors on multiple websites, in order to present relevant advertisement based
on the visitor's preferences. PersistentHTML_uetvid_expMicrosoftContains the
expiry-date for the cookie with corresponding name.
PersistentHTMLMUIDMicrosoftPending1 yearHTTP_gaGoogleUsed to send data to Google
Analytics about the visitor's device and behavior. Tracks the visitor across
devices and marketing channels.2 yearsHTTP_ga_#GoogleUsed to send data to Google
Analytics about the visitor's device and behavior. Tracks the visitor across
devices and marketing channels.2 yearsHTTP_uetsidMicrosoftCollects data on
visitor behaviour from multiple websites, in order to present more relevant
advertisement - This also allows the website to limit the number of times that
they are shown the same advertisement. 0 dayHTTP_uetvidMicrosoftUsed to track
visitors on multiple websites, in order to present relevant advertisement based
on the visitor's preferences. 1 yearHTTP

Unclassified cookies are cookies that we are in the process of classifying,
together with the providers of individual cookies.

NameProviderPurposeExpiryTypeIgnoreTrackerSpottingwww.imdelltra.comPending0
dayHTTP

 [#IABV2_LABEL_PURPOSES#]  [#IABV2_LABEL_FEATURES#]  [#IABV2_LABEL_PARTNERS#]
[#IABV2_BODY_PURPOSES#]
[#IABV2_BODY_FEATURES#]
[#IABV2_BODY_PARTNERS#]

Cookies are small text files that can be used by websites to make a user's
experience more efficient. The law states that we can store cookies on your
device if they are strictly necessary for the operation of this site. For all
other types of cookies  we need your permission.

This site uses different types of cookies. Some cookies are placed by third
party services that appear on our pages.

For further information please visit www.amgen.com/privacy   

Cookie declaration last updated on 22.05.24 by Cookiebot



INDICATIONS

What is IMDELLTRA™ (tarlatamab-dlle)? IMDELLTRA™ is a prescription medicine used
to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which is
cancer that has spread throughout lung or to other parts of the body, and who
have received treatment with chemotherapy that contains platinum, and it did not
work or …READ MORE

What is IMDELLTRA™ (tarlatamab-dlle)?

IMDELLTRA™ is a prescription medicine used to treat adults with extensive-stage
small cell lung cancer (ES-SCLC), which is cancer that has spread throughout
lung or to other parts of the body, and who have received treatment with
chemotherapy that contains platinum, and it did not work or is no longer
working.

It is not known if IMDELLTRA™ is safe and effective in children.

 * Important Safety Information
 * Indication
 * Full Prescribing Information
 * Medication Guide
 * For Healthcare Professionals

 * About Small Cell
   Lung Cancer
 * About
   IMDELLTRA™
   * How IMDELLTRA™ Works
   * Clinical Results
   * Side Effects
 * Starting
   IMDELLTRA™
 * Patient Support
   and Resources
   * Patient Support and Resources
   * Downloads and Support Groups
 * For Healthcare Professionals
 * Important Safety Information
 * Indication






YOU ARE LEAVING IMDELLTRA.COM

You are now leaving IMDELLTRA.com and entering another Amgen website. Amgen is
not adopting such content into this website.


Go back to IMDELLTRA.com Leave the website


YOU ARE LEAVING IMDELLTRA.COM

You are now leaving IMDELLTRA.com and entering another external website. Amgen
is not responsible for the content of the third party website and is not
adopting such content into this website.


Go back to IMDELLTRA.com Leave the website

For adults with extensive-stage small cell lung cancer (ES-SCLC)
who have had prior platinum-based chemotherapy1


MOVE FORWARD WITH IMDELLTRA™

About
IMDELLTRA™Starting treatment
with IMDELLTRA™Patient support
and resources
In a study of 99 adult patients with ES-SCLC who had 2 or more prior treatments,


2 IN 5 PATIENTS (40%) RESPONDED TO IMDELLTRA™,2

which means their tumor shrank or disappeared.3

Based on 99 patients, of which 2 patients saw their tumor completely disappear,
and 38 patients saw their tumor partially shrink by at least 30%.2,4,5

Important Considerations: The approval of IMDELLTRA™ in these patients is based
on a study that measured the size of tumor shrinkage. Talk to your healthcare
provider to see if IMDELLTRA™ is right for you.2,5

Close

See less


IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT IMDELLTRA™?

IMDELLTRA™ MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Cytokine Release Syndrome (CRS). CRS is common during treatment with IMDELLTRA™
and can also be serious or life-threatening. Tell your healthcare provider or
get medical help right away if you develop any signs or symptoms of CRS,
including:

 * fever of 100.4°F (38°C) or higher
 * low blood pressure
 * tiredness
 * fast heartbeat or dizziness
 * headache
 * shortness of breath or trouble breathing

 * nausea and vomiting
 * confusion, restlessness, or feeling anxious
 * problems with balance and movement, such as trouble walking
 * heart, liver, or kidney problems
 * unusual bleeding or bleeding that lasts a long time

DUE TO THE RISK OF CRS, YOU WILL RECEIVE IMDELLTRA™ AS PER THE FOLLOWING
“STEP-UP DOSING SCHEDULE”:

 * The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA™
   on Day 1 of your first treatment cycle (Cycle 1).
 * You will receive the full treatment dose of IMDELLTRA™ on Day 8 and Day 15 of
   Cycle 1. You will receive the full treatment dose 1 time every 2 weeks after
   Day 15 of Cycle 1.
 * If your dose of IMDELLTRA™ is delayed for any reason, you may need to repeat
   the “step-up dosing schedule”.
 * Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA™, you
   will be given a medicine to help reduce your risk of CRS. This will be given
   into your vein by intravenous (IV) infusion. You will also receive IV fluids
   after each of your Cycle 1 doses of IMDELLTRA™ (on Day 1, Day 8 and Day 15).
   Your healthcare provider will decide if you need to receive medicines to help
   reduce your risk of CRS with future doses.

Neurologic Problems. IMDELLTRA™ can cause neurologic problems that can be
serious or life-threatening. Neurologic problems may happen days or weeks after
you receive IMDELLTRA™. Your healthcare provider may refer you to a healthcare
provider who specializes in neurologic problems. Tell your healthcare provider
right away if you develop any signs or symptoms of neurologic problems,
including:

 * trouble speaking, memory loss, or personality changes
 * confusion, feeling disoriented, slow thinking, or not being able to think
   clearly
 * seizure
 * problems with walking, or loss of balance or coordination

 * weakness or numbness of your arms or legs
 * shaking (tremors)
 * headache
 * numbness or tingling of your hands or feet
 * trouble sleeping
 * fainting or loss of consciousness
 * feeling like you have no energy

Due to the risk of CRS and neurologic problems, you will receive the following
monitoring during treatment with IMDELLTRA™:

 * For Day 1 and Day 8 of Cycle 1 doses, your healthcare provider will monitor
   you for 22 to 24 hours from the start of the IMDELLTRA™ infusion in an
   appropriate healthcare setting that can manage these side effects. You should
   remain within 1 hour of an appropriate healthcare setting for a total of 48
   hours from the start of the IMDELLTRA™ infusion after your Day 1 and Day 8 of
   Cycle 1 doses and be accompanied by a caregiver.
 * For Day 15 of Cycle 1 and Cycle 2 doses, your healthcare provider will
   observe you for 6 to 8 hours after the IMDELLTRA™ infusion.
 * For Cycle 3 and Cycle 4 doses, your healthcare provider will watch you for 3
   to 4 hours after the IMDELLTRA™ infusion.
 * For Cycle 5 and later doses, your healthcare provider will watch you for 2
   hours after the IMDELLTRA™ infusion.

Your healthcare provider will monitor you for signs and symptoms of CRS and
neurologic problems during treatment with IMDELLTRA™, as well as other side
effects, and treat you as needed. You may be hospitalized if you develop signs
or symptoms of CRS or neurologic problems during treatment with IMDELLTRA™. Your
healthcare provider may temporarily stop or completely stop your treatment with
IMDELLTRA™ if you develop CRS, neurologic problems, or any other side effects
that are severe.

BEFORE RECEIVING IMDELLTRA™, TELL YOUR HEALTHCARE PROVIDER ABOUT ALL OF YOUR
MEDICAL CONDITIONS, INCLUDING IF YOU:

 * have an infection
 * are pregnant or plan to become pregnant. IMDELLTRA™ may harm your unborn
   baby.

 * FEMALES WHO ARE ABLE TO BECOME PREGNANT:

 * Your healthcare provider should do a pregnancy test before you start
   treatment with IMDELLTRA™.
 * You should use an effective form of birth control (contraception) during
   treatment with IMDELLTRA™, and for 2 months after the last dose of
   IMDELLTRA™.
 * Tell your healthcare provider right away if you become pregnant or think that
   you may be pregnant during treatment with IMDELLTRA™.
 * are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA™ passes
   into your breast milk. Do not breastfeed during treatment with IMDELLTRA™ and
   for 2 months after the last dose of IMDELLTRA™.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.

WHAT SHOULD I AVOID WHILE RECEIVING IMDELLTRA™?

Do not drive, operate heavy or potentially dangerous machinery or do other
dangerous activities, including work-related activities, during treatment with
IMDELLTRA™ if you develop dizziness, confusion, tremors, sleepiness, or any
other symptoms that impair consciousness until your signs and symptoms go away.
These may be signs and symptoms of neurologic problems.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF IMDELLTRA™?

IMDELLTRA™ MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Low white blood cell counts (cytopenia). Decreased blood cell counts are common
with IMDELLTRA™ and can also be severe. IMDELLTRA™ may cause the following low
blood cell counts:

 * low white blood cell counts (neutropenia). Low white blood cells can increase
   your risk for infection.
 * low red blood cell counts (anemia). Low red blood cells can cause tiredness
   and shortness of breath.
 * low platelet counts (thrombocytopenia). Low platelet counts can cause
   bruising or bleeding problems.

Infections. IMDELLTRA™ can cause serious infections that can be life-threatening
and may lead to death. Your healthcare provider will check you for signs and
symptoms of infection before and during treatment with IMDELLTRA™. Tell your
healthcare provider right away if you develop any signs or symptoms of infection
during treatment with IMDELLTRA™, including: fever of 100.4°F (38°C) or higher;
painful rash, cough, sore throat, chest pain, pain during urination, tiredness,
feeling weak or generally unwell, shortness of breath.

Liver problems. IMDELLTRA™ can cause increased liver enzymes and bilirubin in
your blood. These increases can happen with or without you also having CRS. Tell
your healthcare provider if you develop any signs or symptoms of liver problems,
including: tiredness, dark urine, loss of appetite, yellowing of your skin or
the white part of your eyes, pain in your right upper stomach-area (abdomen).

Allergic reactions. IMDELLTRA™ can cause allergic reactions that can be severe.
Go to the nearest emergency room or get medical help right away if you develop
any signs or symptoms of a severe allergic reaction during treatment with
IMDELLTRA™, including: shortness of breath or trouble breathing, coughing, pain
or tightness in your chest and back, feeling lightheaded or dizzy, wheezing,
rash.

Your healthcare provider will do bloodwork before you start and during treatment
with IMDELLTRA™. Your healthcare provider will monitor you for signs or symptoms
of these serious side effects during treatment and may temporarily or completely
stop treatment with IMDELLTRA™ if you develop certain serious side effects.

The most common side effects of IMDELLTRA™ also include: tiredness, muscle or
bone pain, fever, constipation, a bad or metallic taste in your mouth, nausea,
decreased appetite.

These are not all the possible side effects of IMDELLTRA™.

Call your healthcare provider for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.

Please see IMDELLTRA™ full Prescribing Information, including Medication Guide.

WHAT IS IMDELLTRA™ (TARLATAMAB-DLLE)?

IMDELLTRA™ is a prescription medicine used to treat adults with extensive-stage
small cell lung cancer (ES-SCLC), which is cancer that has spread throughout
lung or to other parts of the body, and who have received treatment with
chemotherapy that contains platinum, and it did not work or is no longer
working.

It is not known if IMDELLTRA™ is safe and effective in children.


References: 1. IMDELLTRA™ (tarlatamab-dlle) medication guide, Amgen. 2.
IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen. 3. Delgado A, et
al. Am J Cancer Res. 2021;11:1121-1131. 4. National Cancer Institute. NCI
Dictionary of Cancer Terms.
https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 4,
2024. 5. Aykan NF, et al. World J Clin Oncol. 2020;11:53-73.

References: 1. National Cancer Institute. NCI Dictionary of Cancer Terms.
https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 4,
2024. 2. American Cancer Society. www.cancer.org. Accessed April 4, 2024. 3.
IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen.

References: 1. IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen. 2.
Einsele H, et al. Cancer. 2020;126:3192-3201.

References: 1. IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen. 2.
Delgado A, et al. Am J Cancer Res. 2021;11:1121-1131. 3. Eisenhauer EA, et al.
Eur J Cancer. 2009;45:228-247. 4. Aykan NF, et al. World J Clin Oncol.
2020;11:53-73.

References: 1. IMDELLTRA™ (tarlatamab-dlle) medication guide, Amgen. 2.
Shimabukuro-Vornhagen A, et al. J Immunother Cancer. 2018;6:56.

References: 1. IMDELLTRA™ (tarlatamab-dlle) medication guide, Amgen. 2.
IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen.

See more




IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT IMDELLTRA™?

IMDELLTRA™ MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Cytokine Release Syndrome (CRS). CRS is common during treatment with IMDELLTRA™
and can also be serious or life-

ABOUT SMALL CELL LUNG CANCER
 * About Small Cell Lung Cancer

ABOUT IMDELLTRA™
 * How IMDELLTRA™ works
 * Clinical results
 * Side effects

STARTING IMDELLTRA™
 * Starting IMDELLTRA™

PATIENT SUPPORT AND
RESOURCES
 * Patient support and resources
 * Downloads and support groups

Contact Us Privacy Statement Terms of Use Consumer Health Data Privacy Policy
Cookie Settings Amgen Medinfo



© 2024 Amgen Inc. All rights reserved. 5/24

This website is intended for use in the US only.



 * 
 * 
 *